- Latest available (Revised)
- Original (As adopted by EU)
Commission Decision of 18 December 2008 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2009 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council on substances that deplete the ozone layer (notified under document number C(2008) 8398) (Only the Dutch, English, French, German, Italian, Slovenian and Spanish texts are authentic) (2009/52/EC)
You are here:
What Version
More Resources
Legislation originating from the EU
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
This item of legislation originated from the EU
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Status:
This is the original version as it was originally adopted in the EU.
This legislation may since have been updated - see the latest available (revised) version
ANNEX I
Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:
LIST OF NON-ESSENTIAL SUBSTANCES
| Table 1 | |||||||||||
| Short-acting beta agonist bronchodilators | |||||||||||
| Country | Salbutamol | Terbutaline | Fenoterol | Orciprenaline | Reproterol | Carbuterol | Hexoprenaline | Pirbuterol | Clenbuterol | Bitolterol | Procaterol |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | X | X | X | X | X | X | X | X | X | X | X |
| Belgium | X | X | X | X | X | X | X | X | X | X | X |
| Bulgaria | X | X | X | X | X | X | X | X | X | X | X |
| Cyprus | X | X | X | X | X | X | X | X | X | X | X |
| Czech Republic | X | X | X | X | X | X | X | X | X | X | X |
| Denmark | X | X | X | X | X | X | X | X | X | X | X |
| Estonia | X | X | X | X | X | X | X | X | X | X | X |
| Finland | X | X | X | X | X | X | X | X | X | X | X |
| France | X | X | X | X | X | X | X | X | X | X | X |
| Germany | X | X | X | X | X | X | X | X | X | X | X |
| Greece | X | X | X | X | X | X | X | X | X | X | X |
| Hungary | X | X | X | X | X | X | X | X | X | X | X |
| Ireland | X | X | X | X | X | X | X | X | X | X | X |
| Italy | X | X | X | X | X | X | X | X | X | X | X |
| Latvia | X | X | X | X | X | X | X | X | X | X | X |
| Lithuania | X | X | X | X | X | X | X | X | X | X | X |
| Luxembourg | X | X | X | X | X | X | X | X | X | X | X |
| Malta | X | X | X | X | X | X | X | X | X | X | X |
| Netherlands | X | X | X | X | X | X | X | X | X | X | X |
| Poland | X | X | X | X | X | X | X | X | X | X | X |
| Portugal | X | X | X | X | X | X | X | X | X | X | X |
| Romania | X | X | X | X | X | X | X | X | X | X | X |
| Slovakia | X | X | X | X | X | X | X | X | X | X | X |
| Slovenia | X | X | X | X | X | X | X | X | X | X | X |
| Spain | X | X | X | X | X | X | X | X | X | X | X |
| Sweden | X | X | X | X | X | X | X | X | X | X | X |
| United Kingdom | X | X | X | X | X | X | X | X | X | X | X |
| Table 2 | ||||||
| Inhaled steroids | ||||||
| Country | Beclomethasone | Dexamethasone | Flunisolide | Fluticasone | Budesonide | Triamcinolone |
|---|---|---|---|---|---|---|
| Austria | X | X | X | X | X | X |
| Belgium | X | X | X | X | X | X |
| Bulgaria | X | X | X | X | X | X |
| Cyprus | X | X | X | X | X | X |
| Czech Republic | X | X | X | X | X | X |
| Denmark | X | X | X | X | X | X |
| Estonia | X | X | X | X | X | X |
| Finland | X | X | X | X | X | X |
| France | X | X | X | X | X | X |
| Germany | X | X | X | X | X | X |
| Greece | X | X | X | X | X | X |
| Hungary | X | X | X | X | X | X |
| Ireland | X | X | ||||
| Italy | X | X | X | X | X | X |
| Latvia | X | X | X | X | X | X |
| Lithuania | X | X | X | X | X | X |
| Luxembourg | X | X | X | X | X | X |
| Malta | X | X | ||||
| Netherlands | X | X | X | X | X | X |
| Poland | X | X | X | X | X | X |
| Portugal | X | X | X | X | X | X |
| Romania | X | X | X | X | X | X |
| Slovakia | X | X | X | X | X | X |
| Slovenia | X | X | X | X | X | X |
| Spain | X | X | X | X | X | X |
| Sweden | X | X | X | X | X | X |
| United Kingdom | X | |||||
| Table 3 | ||
| Non-steroidal anti-inflammatories | ||
| Country | Cromoglicic acid | Nedrocromil |
|---|---|---|
| Austria | X | X |
| Belgium | X | X |
| Bulgaria | X | X |
| Cyprus | X | X |
| Czech Republic | X | X |
| Denmark | X | X |
| Estonia | X | X |
| Finland | X | X |
| France | X | X |
| Germany | X | X |
| Greece | X | X |
| Hungary | X | |
| Ireland | ||
| Italy | X | X |
| Latvia | X | X |
| Lithuania | X | X |
| Luxembourg | X | |
| Malta | X | |
| Netherlands | X | X |
| Poland | X | X |
| Portugal | X | |
| Romania | X | X |
| Slovakia | X | X |
| Slovenia | X | X |
| Spain | X | X |
| Sweden | X | X |
| United Kingdom | X | X |
| Table 4 | ||
| Anticholinergic bronchodilators | ||
| Country | Ipratropium bromide | Oxitropium bromide |
|---|---|---|
| Austria | X | X |
| Belgium | X | X |
| Bulgaria | X | X |
| Cyprus | X | X |
| Czech Republic | X | X |
| Denmark | X | X |
| Estonia | X | X |
| Finland | X | X |
| France | X | X |
| Germany | X | X |
| Greece | X | X |
| Hungary | X | X |
| Ireland | X | X |
| Italy | X | |
| Latvia | X | X |
| Lithuania | X | X |
| Luxembourg | X | X |
| Malta | X | X |
| Netherlands | X | X |
| Poland | X | X |
| Portugal | X | |
| Romania | X | X |
| Slovakia | X | X |
| Slovenia | X | X |
| Spain | X | X |
| Sweden | X | X |
| United Kingdom | X | X |
| Table 5 | ||
| Long-acting beta agonist bronchodilators | ||
| Country | Formoterol | Salmeterol |
|---|---|---|
| Austria | X | X |
| Belgium | X | X |
| Bulgaria | X | X |
| Cyprus | X | X |
| Czech Republic | X | X |
| Denmark | X | X |
| Estonia | X | X |
| Finland | X | X |
| France | X | X |
| Germany | X | X |
| Greece | X | X |
| Hungary | X | X |
| Ireland | X | X |
| Italy | X | X |
| Latvia | X | X |
| Lithuania | X | X |
| Luxembourg | X | X |
| Malta | X | X |
| Netherlands | X | X |
| Poland | X | X |
| Portugal | X | X |
| Romania | X | X |
| Slovakia | X | X |
| Slovenia | X | X |
| Spain | X | X |
| Sweden | X | X |
| United Kingdom | X | X |
| Table 6 | ||
| Combinations of active ingredients in a single MDI | ||
| Country | ||
|---|---|---|
| Austria | X All products | |
| Belgium | X All products | |
| Bulgaria | X All products | |
| Cyprus | ||
| Czech Republic | X All products | |
| Denmark | X All products | |
| Estonia | ||
| Finland | X All products | |
| France | X All products | |
| Germany | X All products | |
| Greece | ||
| Hungary | X All products | |
| Ireland | ||
| Italy | Budesonide + Fenoterol | Fluticasone + Salmeterol |
| Latvia | X All products | |
| Lithuania | X All products | |
| Luxembourg | X All products | |
| Malta | X All products | |
| Netherlands | X All products | |
| Poland | X All products | |
| Portugal | X All products | |
| Romania | X All products | |
| Slovakia | X All products | |
| Slovenia | X All products | |
| Spain | ||
| Sweden | X All products | |
| United Kingdom | ||
Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Options/Help
Print Options
PrintThe Whole Decision
PrintThis Annex only
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Opening Options
Different options to open legislation in order to view more content on screen at once
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the EU Official Journal
- lists of changes made by and/or affecting this legislation item
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as adopted version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.